CBLL
CeriBell, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +3.0% ·
net new positions -7.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.48M | -7.4% | $51.49M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 1.69M | +11.1% | $19.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 1.47M | +11.1% | $16.93M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | JPMorgan Chase ✦ | 822.36K | n/a | $9.45M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 5 | Millennium Management ✦ | 666.45K | +41.8% | $7.66M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 581.93K | +29.9% | $6.69M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 412.94K | +7.4% | $4.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 297.96K | +81.0% | $3.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 154.54K | n/a | $1.78M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 10 | Marshall Wace ✦ | 46.78K | +6.0% | $537,456 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 13.04K | +4.6% | $150,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 10.59K | n/a | $121,702 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 3.42K | -94.8% | $39,287 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $1.43M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 121 holders, 29.58M shares, $536.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.89K sh · $119,145
Officer, Director · 20.85K sh · $521,775
Officer · 846 sh · $21,150
Officer · 7.50K sh · $181,875
Officer · 1.75K sh · $42,576
Officer · 4.89K sh · $118,901
Officer · 652 sh · $16,300
Officer, Director · 39.54K sh · $973,079
Officer · 859 sh · $20,573
Officer, Director · 6.07K sh · $145,753
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology